LONDON, ONTARIO--(Marketwire - December 18, 2007) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that the Company intends to prepare a Phase 1B Health Canada clinical trial submission based on positive preclinical results for its small cell lung cancer (SCLC) drug, COTI-2. The Company anticipates that the first patient will be registered in a Phase 1B trial in 12-15 months.
